跳至主要内容
临床试验/NCT05635357
NCT05635357已完成不适用

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Anastrozole vs Exemestane/Letrozole

Brigham and Women's Hospital1 个研究点 分布在 1 个国家目标入组 16,989 人开始时间: 2022年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
16,989
试验地点
1
主要终点
Time to dementia onset

研究概览

简要总结

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

详细描述

This is a non-randomized, non-interventional study that is part of the DREAM Study of Brigham and Women's Hospital. DREAM is led by Dr. Madhav Thambisetty, MD, PhD, Chief of the Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA) intramural research program. This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication using healthcare claims data.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged >/= 65 years on the index date
  • Enrollment in Medicare Part A, B, and D with no HMO coverage for 365 days prior to and including cohort entry date
  • At least two claims with breast cancer diagnosis measured 365 days prior to drug initiation

排除标准

  • Prior history of dementia measured anytime prior to cohort entry date
  • Prior history of nursing home admission anytime prior to cohort entry date
  • Prior history of Anastrozole or Exemestane/Letrozole use anytime prior to cohort entry date

研究组 & 干预措施

Anastrozole

Exposure group

干预措施: Anastrozole (Drug)

Exemestane/Letrozole

Reference group

干预措施: Exemestane/Letrozole (Drug)

结局指标

主要结局

Time to dementia onset

时间窗: up to 6 years

Time to dementia onset, i.e., Alzheimer's disease, vascular dementia, senile, presenile, or unspecified dementia, or dementia in other diseases classified elsewhere. Please refer to uploaded protocol for full definition due to size limitations.

次要结局

  • Time to Alzheimer's disease onset(up to 6 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rishi J. Desai

Assistant Professor of Medicine

Brigham and Women's Hospital

研究点 (1)

Loading locations...

相似试验